img-007
mAbexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2022 (NCT05353972)
Timeline
Indications
Mechanism of action
TNFSF4 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07037901 | Phase 2 | Jun 17, 2025 | Inmagene Biopharmaceuticals |
| NCT06304740 | Phase 1 | Mar 6, 2024 | Inmagene Biopharmaceuticals |
| NCT06060977 | Phase 1/Phase 2 (Phase 2) | Sep 25, 2023 | Inmagene Biopharmaceuticals |
| NCT05984784 | Phase 1/Phase 2 (Phase 2) | Aug 9, 2023 | Inmagene Biopharmaceuticals |
| NCT05353972 | Phase 1 | Jun 30, 2022 | Inmagene Biopharmaceuticals |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Inmagene Biopharmaceuticals | For profit | 5 | 5 | 2 | 2022 |
1 organizations
Page 1 / 1